论文部分内容阅读
目的研究诃子水提物对泛耐药鲍曼不动杆菌(PDR-Ab)的抑菌作用。方法采用二倍稀释法测定诃子水提物对临床分离的泛耐药鲍曼不动杆菌的最低抑菌浓度(MIC)和最低杀菌浓度(MBC)。小鼠腹腔注射上述PDR-Ab,建立急性肺炎模型。于造模前4天至造模后2天对小鼠连续灌胃给药,考察小鼠的死亡率、血液白细胞计数及肺组织病理变化。结果体外实验表明诃子水提物能抑制PDR-Ab在液体培养基中的生长,MIC和MBC分别为0.75 mg/m L和12 mg/m L。体内实验表明,剂量为150 mg/kg诃子水提物灌胃给药能明显降低PDR-Ab感染性急性肺炎小鼠的死亡率,使血液白细胞计数较快恢复,肺组织病理改善明显。结论诃子水提物对PDR-Ab在体内外均具有明显的抑菌作用,有望用于PDR-Ab感染性疾病的治疗。
Objective To study the bacteriostasis of myrobalan extract against Acinetobacter baumannii (PDR-Ab). Methods The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of myrobalan extract against clinically isolated pan-drug-resistant Acinetobacter baumannii were determined by double dilution method. The mice were injected intraperitoneally with PDR-Ab to establish an acute pneumonia model. Mice were given gavage four days before model making to 2 days after model making. The mortality, blood leukocyte count and pathological changes in lung tissue were examined. Results In vitro experiments showed that myrobalan extract could inhibit the growth of PDR-Ab in liquid medium with MIC and MBC of 0.75 mg / m L and 12 mg / m L, respectively. In vivo experiments showed that the dosage of 150mg / kg myrobalan water-perfusion administration can significantly reduce the mortality of mice infected with PDR-Ab-infected acute pneumonia, the rapid recovery of blood leukocyte count, lung tissue pathology improved significantly. Conclusion Myrobalan extract against PDR-Ab in vitro and in vivo have obvious antibacterial activity, is expected to be used for the treatment of PDR-Ab infectious diseases.